References
- EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201627suppl 5v58v6827664262
- Kidney Cancer Incidence Statistics [webpage on the Internet]Cancer Research UK2015 Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer/incidenceAccessed November 21, 2017
- KimDYWoodCGKaramJATreating the two extremes in renal cell carcinoma: management of small renal masses and cytoreductive nephrectomy in metastatic diseaseAm Soc Clin Oncol Educ Book2014e214e22110.14694/EdBook_AM.2014.34.e21424857105
- GuptaKMillerJDLiJZRussellMWCharbonneauCEpidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature reviewCancer Treat Rev200834319320518313224
- DelacroixSWoodCJonaschERenal neoplasiaBrennerBMChertowGMMarsdenPASkoreckiKSYuASBrenner and Rector’s The Kidney9th edPhiladelphia, PA, USAElsevier Saunders201115081528
- NICE [webpage on the Internet]Bevacizumab (First-line), Sorafenib (First- and Second-line), Sunitinib (Second-line) and Temsirolimus (First-line) for the Treatment of Advanced and/or Metastatic Renal Cell CarcinomaNICE2017 Available from: https://www.nice.org.uk/Guidance/TA178Accessed November 21, 2017
- ChoueiriTKEscudierBPowlesTCabozantinib versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191814182326406150
- ChoueiriTKEscudierBPowlesTCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialLancet Oncol201617791792727279544
- AmzalBFuSMengJListerJKarcherHCabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinomaPLoS One2017129e018442328886175
- SchmidingerMDanesiRManagement of adverse events associated with cabozantinib therapy in renal cell carcinomaOncologist201723330631529146618
- MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181310.1056/NEJMoa151066526406148
- NICE [webpage on the Internet]Guide to the Methods of Technology Appraisal 2013NICE2017 Available from: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case#discountingAccessed December 11, 2017
- ElsadaAAdlerAINICE guidance on cabozantinib for previously treated advanced renal cell carcinomaLancet Oncol20171891153115428800862
- EscudierBEisenTStadlerWMSorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialJ Clin Oncol200927203312331819451442
- ShermanSAmzalBCalvoEAn indirect comparison of everolimus versus axitinib in US patients with advanced renal cell carcinoma in whom prior sunitinib therapy failedClin Ther201510.1016/j.clinthera.2015.09.013
- NICE [webpage on the Internet]Cabozantinib for Previously Treated Advanced Renal Cell CarcinomaNICE2017 Available from: https://www.nice.org.uk/guidance/ta463Accessed November 21, 2017
- NICE [webpage on the Internet]Nivolumab for Previously Treated Advanced Renal Cell CarcinomaNICE2017 Available from: https://www.nice.org.uk/guidance/ta417/evidenceAccessed November 24, 2017
- HerdmanMGudexCLloydADevelopment and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Qual Life Res201120101727173621479777
- BNF Publications [webpage on the Internet]BooksBNF Publications2017 Available from: https://www.bnf.org/products/books/Accessed November 21, 2017
- Exelixis. XL 184–308. A phase 3, randomized, controlled study of cabozantinib (XL184) vs everolimus in subjects with metastatic renal cell carcinoma that has progressed after prior VEGFR tyrosine kinase inhibitor therapy. NCT01865747; 2015.
- RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
- NICE [webpage on the Internet]Nivolumab for Previously Treated Advanced Renal Cell CarcinomaNICE2017 Available from: https://www.nice.org.uk/guidance/ta417Accessed November 21, 2017
- PSSRU [webpage on the Internet]Unit Costs of Health and Social Care 2015PSSRU2017 Available from: http://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2015/Accessed November 21, 2017
- GOV.UK [webpage on the Internet]NHS Reference Costs 2014 to 2015GOV.UK2017 Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015Accessed November 21, 2017
- The Nuffield Trust [webpage on the Internet]Exploring the Cost of Care at the End of LifeThe Nuffield Trust2017 Available from: https://www.nuffieldtrust.org.uk/research/exploring-the-cost-of-care-at-the-end-of-lifeAccessed November 21, 2017
- Inflation [webpage on the Internet]Historic Inflation Great Britain – Historic CPI Inflation Great Britain2017 Available from: http://www.inflation.eu/inflation-rates/great-britain/historic-inflation/cpi-inflation-great-britain.aspxAccessed November 21, 2017